

Barbara M Fischer

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5298586/publications.pdf>

Version: 2024-02-01

64
papers

1,325
citations

430874

18
h-index

377865

34
g-index

66
all docs

66
docs citations

66
times ranked

2027
citing authors

#	ARTICLE	IF	CITATIONS
1	Testâ€“retest repeatability and interobserver variation of healthy tissue metabolism using 18F-FDG PET/CT of the thorax among lung cancer patients. Nuclear Medicine Communications, 2022, 43, 549-559.	1.1	3
2	A Literature Review on the Use of Artificial Intelligence for the Diagnosis of COVID-19 on CT and Chest X-ray. Diagnostics, 2022, 12, 869.	2.6	10
3	Deep learning for Dixon MRI-based attenuation correction in PET/MRI of head and neck cancer patients. EJNMMI Physics, 2022, 9, 20.	2.7	5
4	Multi-parametric PET/MRI for enhanced tumor characterization of patients with cervical cancer. European Journal of Hybrid Imaging, 2022, 6, 7.	1.5	3
5	A Long Axial Field of View Enables PET/CT in Toddler Without Sedation. Journal of Nuclear Medicine, 2022, 63, 1962-1962.	5.0	9
6	New PET Tracers: Current Knowledge and Perspectives in Lung Cancer. Seminars in Nuclear Medicine, 2022, 52, 781-796.	4.6	7
7	Artificial Intelligence for the Characterization of Pulmonary Nodules, Lung Tumors and Mediastinal Nodes on PET/CT. Seminars in Nuclear Medicine, 2021, 51, 143-156.	4.6	16
8	¹⁸ F-FLT PET/CT Adds Value to ¹⁸ F-FDG PET/CT for Diagnosing Relapse After Definitive Radiotherapy in Patients with Lung Cancer: Results of a Prospective Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 628-635.	5.0	8
9	Prognostic Value of 18Fâ€“FDGâ€“PET Parameters in Patients with Small Cell Lung Cancer: A Meta-Analysis and Review of Current Literature. Diagnostics, 2021, 11, 174.	2.6	9
10	Impact of [18F]FDG-PET and [18F]FLT-PET-Parameters in Patients with Suspected Relapse of Irradiated Lung Cancer. Diagnostics, 2021, 11, 279.	2.6	3
11	Effect of Follow-Up Surveillance After Curative-Intent Treatment of NSCLC on Detection of New and Recurrent Disease, Retreatment, and Survival: A Systematic Review and Meta-Analysis. Journal of Thoracic Oncology, 2021, 16, 784-797.	1.1	7
12	Intratumor heterogeneity is biomarker specific and challenges the association with heterogeneity in multimodal functional imaging in head and neck squamous cell carcinoma. European Journal of Radiology, 2021, 139, 109668.	2.6	4
13	Toward PET/MRI as one-stop shop for radiotherapy planning in cervical cancer patients. Acta OncolÃ³gica, 2021, 60, 1045-1053.	1.8	15
14	FDG PET/CT for Detection of Infectious Complications Following Solid Organ Transplantation. Seminars in Nuclear Medicine, 2021, 51, 321-334.	4.6	3
15	Robustness and Generalizability of Deep Learning Synthetic Computed Tomography for Positron Emission Tomography/Magnetic Resonance Imagingâ€“Based Radiation Therapy Planning of Patients With Head and Neck Cancer. Advances in Radiation Oncology, 2021, 6, 100762.	1.2	7
16	Positron emission tomography-computed tomography (PET-CT) in suspected malignant pleural effusion. An updated systematic review and meta-analysis. Lung Cancer, 2021, 162, 106-118.	2.0	13
17	Heterogeneity in tumours: Validating the use of radiomic features on 18F-FDG PET/CT scans of lung cancer patients as a prognostic tool. Radiotherapy and Oncology, 2020, 144, 72-78.	0.6	35
18	Surveillance With PET/CT and Liquid Biopsies of Stage I-III Lung Cancer Patients After Completion of Definitive Therapy: A Randomized Controlled Trial (SUPER). Clinical Lung Cancer, 2020, 21, e61-e64.	2.6	7

#	ARTICLE	IF	CITATIONS
19	Feasibility of Multiparametric Positron Emission Tomography/Magnetic Resonance Imaging as a One-Stop Shop for Radiation Therapy Planning for Patients with Head and Neck Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1329-1338.	0.8	14
20	Does multiparametric imaging with 18F-FDG-PET/MRI capture spatial variation in immunohistochemical cancer biomarkers in head and neck squamous cell carcinoma?. <i>British Journal of Cancer</i> , 2020, 123, 46-53.	6.4	13
21	Circulating cell free DNA during definitive chemo-radiotherapy in non-small cell lung cancer patients – initial observations. <i>PLoS ONE</i> , 2020, 15, e0231884.	2.5	11
22	18F-fluorothymidine (FLT)-PET and diffusion-weighted MRI for early response evaluation in patients with small cell lung cancer: a pilot study. <i>European Journal of Hybrid Imaging</i> , 2020, 4, 2.	1.5	2
23	Title is missing!. , 2020, 15, e0231884.		0
24	Title is missing!. , 2020, 15, e0231884.		0
25	Title is missing!. , 2020, 15, e0231884.		0
26	Title is missing!. , 2020, 15, e0231884.		0
27	PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma. <i>European Archives of Oto-Rhino-Laryngology</i> , 2019, 276, 2895-2902.	1.6	5
28	Calcium electroporation for recurrent head and neck cancer: A clinical phase I study. <i>Laryngoscope Investigative Otolaryngology</i> , 2019, 4, 49-56.	1.5	39
29	Computed tomography of the chest in unilateral pleural effusions: outcome of the British Thoracic Society guideline. <i>Journal of Thoracic Disease</i> , 2019, 11, 1336-1346.	1.4	4
30	Preparing data for multiparametric PET/MR imaging: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of [18F]FDG-PET and diffusion-weighted MRI in head and neck cancer. <i>Physica Medica</i> , 2019, 61, 1-7.	0.7	8
31	Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma. <i>British Journal of Cancer</i> , 2019, 120, 1003-1006.	6.4	109
32	Very Early Response Evaluation by PET/MR in Patients with Lung Cancer – Timing and Feasibility. <i>Diagnostics</i> , 2019, 9, 35.	2.6	5
33	PET/DW-MRI for evaluating treatment in chronic hepatitis C patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2019, 9, 84-92.	1.0	1
34	Effect of <i>Lactobacillus rhamnosus</i> GG Supplementation on Intestinal Inflammation Assessed by PET/MRI Scans and Gut Microbiota Composition in HIV-Infected Individuals. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 78, 450-457.	2.1	26
35	A Competing Risk Model of First Failure Site after Definitive Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2018, 13, 559-567.	1.1	16
36	Reproducibility of MR-Based Attenuation Maps in PET/MRI and the Impact on PET Quantification in Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2018, 59, 999-1004.	5.0	15

#	ARTICLE	IF	CITATIONS
37	[OA141] Preparing data for multiparametric PET/MRI: Influence of PET point spread function modelling and EPI distortion correction on the spatial correlation of 18F-FDG-PET uptake and diffusion weighted MRI in head/neck cancer. <i>Physica Medica</i> , 2018, 52, 54.	0.7	0
38	A clinical prognostic model compared to the newly adopted UICC staging in an independent validation cohort of P16 negative/positive head and neck cancer patients. <i>Oral Oncology</i> , 2018, 81, 52-60.	1.5	8
39	Repeatability of FDG PET/CT metrics assessed in free breathing and deep inspiration breath hold in lung cancer patients. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 8, 127-136.	1.0	2
40	A failure-type specific risk prediction tool for selection of head-and-neck cancer patients for experimental treatments. <i>Oral Oncology</i> , 2017, 74, 77-82.	1.5	10
41	Immunohistochemical and molecular imaging biomarker signature for the prediction of failure site after chemoradiation for head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2017, 56, 1562-1570.	1.8	9
42	A Prospective Study Comparing ^{99m} Tc-Hydroxyethylene-Diphosphonate Planar Bone Scintigraphy and Whole-Body SPECT/CT with ¹⁸ F-Fluoride PET/CT and ¹⁸ F-Fluoride PET/MRI for Diagnosing Bone Metastases. <i>Journal of Nuclear Medicine</i> , 2017, 58, 1778-1785.	5.0	67
43	Feasibility of Multiparametric Imaging with PET/MR in Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2017, 58, 69-74.	5.0	44
44	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. <i>Diagnostics</i> , 2017, 7, 23.	2.6	13
45	The value of FDG PET/CT for follow-up of patients with melanoma: a retrospective analysis. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 7, 255-262.	1.0	15
46	Phase I trial of 18F-Fludeoxyglucose based radiation dose painting with concomitant cisplatin in head and neck cancer. <i>Radiotherapy and Oncology</i> , 2016, 120, 76-80.	0.6	55
47	PET/CT is a cost-effective tool against cancer: synergy supersedes singularity. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1749-1752.	6.4	19
48	Early lesion-specific 18F-FDG PET response to chemotherapy predicts time to lesion progression in locally advanced non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2016, 118, 460-464.	0.6	11
49	Prognostic value of 18F-fludeoxyglucose uptake in 287 patients with head and neck squamous cell carcinoma. <i>Head and Neck</i> , 2015, 37, 1274-1281.	2.0	18
50	Dental artifacts in the head and neck region: implications for Dixon-based attenuation correction in PET/MR. <i>EJNMMI Physics</i> , 2015, 2, 8.	2.7	18
51	Spatio-temporal stability of pre-treatment 18F-Fludeoxyglucose uptake in head and neck squamous cell carcinomas sufficient for dose painting. <i>Acta Oncologica</i> , 2015, 54, 1416-1422.	1.8	14
52	Immunohistochemical biomarkers and FDG uptake on PET/CT in head and neck squamous cell carcinoma. <i>Acta Oncologica</i> , 2015, 54, 1408-1415.	1.8	26
53	PET/CT in therapy evaluation of patients with lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 595-620.	2.4	8
54	Geometric distortions of diffusion weighted imaging of the head/neck in combined PET/MR: optimization of image acquisition and post-processing correction for oncology applications. <i>EJNMMI Physics</i> , 2014, 1, A76.	2.7	3

#	ARTICLE	IF	CITATIONS
55	The role of positron emission tomography for evaluation of lung nodules and staging lung cancer. <i>Current Respiratory Care Reports</i> , 2012, 1, 30-39.	0.6	1
56	PET/MR in oncology: an introduction with focus on MR and future perspectives for hybrid imaging. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2012, 2, 458-74.	1.0	44
57	Feasibility of FDG-PET/CT imaging during concurrent chemo-radiotherapy in patients with locally advanced pancreatic cancer. <i>Acta Oncol</i> , 2011, 50, 1250-1252.	1.8	6
58	PET-CT in Preoperative Staging of Lung Cancer. <i>New England Journal of Medicine</i> , 2011, 364, 980-981.	27.0	19
59	Multimodality approach to mediastinal staging in non-small cell lung cancer. Faults and benefits of PET-CT: a randomised trial. <i>Thorax</i> , 2011, 66, 294-300.	5.6	73
60	How to study optimal timing of PET/CT for monitoring of cancer treatment. <i>American Journal of Nuclear Medicine and Molecular Imaging</i> , 2011, 1, 54-62.	1.0	30
61	PET/CT imaging in response evaluation of patients with small cell lung cancer. <i>Lung Cancer</i> , 2006, 54, 41-49.	2.0	54
62	How few cancer cells can be detected by positron emission tomography? A frequent question addressed by an in vitro study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006, 33, 697-702.	6.4	59
63	The Future in Diagnosis and Staging of Lung Cancer: Positron Emission Tomography. <i>Respiration</i> , 2006, 73, 267-276.	2.6	54
64	Positron-emission tomography in prognostic and therapeutic assessment of lung cancer: systematic review. <i>Lancet Oncology</i> , 2004, 5, 531-540.	10.7	213